Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
Elizabeth R. Gerstner(University of California, Los Angeles), Tracy T. Batchelor(Brigham and Women's Hospital), Dan G. Duda(Harvard University), Ciprian Catana(Massachusetts General Hospital), Jacob M. Hooker(Massachusetts General Hospital), Jayashree Kalpathy–Cramer(University of Colorado Denver), Bruce R. Rosen(Massachusetts General Hospital), Jörg Dietrich(Massachusetts General Hospital), Yi‐Fen Yen(Harvard University), Justin T. Jordan(Massachusetts General Hospital), Kevin Lou Wenchin(Massachusetts General Hospital), Kyrre E. Emblem(Oslo University Hospital)
Cited by 17
Related Papers
3D Slicer as an image computing platform for the Quantitative Imaging Network
|Magnetic Resonance Imaging|2012|9.1k
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)
|IEEE Transactions on Medical Imaging|2014|6.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
|Nature Clinical Practice Oncology|2006|1k